1
|
Fujioka Y, Ueki H, A R, Sasajima A, Tomono T, Ukawa M, Yagi H, Sakuma S, Kitagawa K, Shirakawa T. The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine. Int J Mol Sci 2024; 25:5997. [PMID: 38892182 PMCID: PMC11173103 DOI: 10.3390/ijms25115997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2024] [Revised: 05/25/2024] [Accepted: 05/27/2024] [Indexed: 06/21/2024] Open
Abstract
Cancer immunotherapy using antigen-pulsed dendritic cells can induce strong cellular immune responses by priming cytotoxic T lymphocytes. In this study, we pulsed tumor cell lysates with VP-R8, a cell-penetrating D-octaarginine-linked co-polymer of N-vinylacetamide and acrylic acid (PNVA-co-AA), into the DC2.4 murine dendritic cell line to improve antigen uptake and then determined the anti-tumor effect in tumor-bearing mice. DC2.4 cells were pulsed with the cell lysate of EL4, a murine lymphoma cell line, and VP-R8 to generate the DC2.4 vaccine. For the in vivo study, DC2.4 cells pulsed with EL4 lysate and VP-R8 were subcutaneously injected into the inguinal lymph node to investigate the anti-tumor effect against EL4 and EL4-specific T cell immune responses. VP-R8 significantly improved antigen uptake into DC2.4 compared to conventional keyhole limpet hemocyanin (p < 0.05). The expression of MHC class I, MHC class II, and CD86 in DC2.4 cells significantly increased after pulsing tumor lysates with VP-R8 compared to other treatments (p < 0.05). The intra-lymph node injection of DC2.4 pulsed with both VP-R8 and EL4 lysate significantly decreased tumor growth compared to DC2.4 pulsed with KLH and lysates (p < 0.05) and induced tumor-infiltrating CD8T cells. The DC2.4 vaccine also remarkably increased the population of IFN-gamma-producing T cells and CTL activity against EL4 cells. In conclusion, we demonstrated that VP-R8 markedly enhances the efficiency of dendritic cell-based vaccines in priming robust anti-tumor immunity, suggesting its potential as a beneficial additive for dendritic cell-based immunotherapy.
Collapse
Affiliation(s)
- Yuri Fujioka
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
| | - Hideto Ueki
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
- Department of Urology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan
| | - Ruhan A
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
| | - Akari Sasajima
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
| | - Takumi Tomono
- Faculty of Pharmaceutical Sciences, Setsunan University, Osaka 573-0101, Japan; (T.T.); (M.U.); (H.Y.); (S.S.)
| | - Masami Ukawa
- Faculty of Pharmaceutical Sciences, Setsunan University, Osaka 573-0101, Japan; (T.T.); (M.U.); (H.Y.); (S.S.)
| | - Haruya Yagi
- Faculty of Pharmaceutical Sciences, Setsunan University, Osaka 573-0101, Japan; (T.T.); (M.U.); (H.Y.); (S.S.)
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences, Setsunan University, Osaka 573-0101, Japan; (T.T.); (M.U.); (H.Y.); (S.S.)
| | - Koichi Kitagawa
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
| | - Toshiro Shirakawa
- Department of Advanced Medical Science, Graduate School of Science, Technology and Innovation, Kobe University, Kobe 650-0017, Japan; (Y.F.); (H.U.); (R.A.); (A.S.); (K.K.)
- Department of Urology, Graduate School of Medicine, Kobe University, Kobe 650-0017, Japan
| |
Collapse
|
2
|
OKAMOTO M, MIURA A, ITO R, KAMADA T, MIZUKAMI Y, KAWAMOTO K. G-protein-coupled estrogen receptor prevents nuclear factor-kappa B promoter activation by Helicobacter pylori cytotoxin-associated gene A in gastric cancer cells. J Vet Med Sci 2023; 85:1348-1354. [PMID: 37952974 PMCID: PMC10788165 DOI: 10.1292/jvms.23-0054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 10/20/2023] [Indexed: 11/14/2023] Open
Abstract
Helicobacter pylori is a well-known pathogen that causes chronic gastritis, leading to the development of gastric cancer. This bacterium has also been detected in dogs, and symptoms similar to those in humans have been reported. The cytotoxin-associated gene A (CagA) is involved in pathogenesis through aberrant activation of host signal transduction, including the nuclear factor-kappa B (NF-κB) pathway. We have previously shown the anti-inflammatory effect of the G-protein-coupled estrogen receptor (GPER) via inhibiting of NF-κB activation in several cells. Therefore, here, we investigated the effect of GPER on CagA-mediated NF-κB promoter activity and showed that CagA overexpression in gastric cancer cells activated the NF-κB reporter and induced interleukin 8 (il-8) expression, both of which were inhibited by the GPER agonist.
Collapse
Affiliation(s)
- Mariko OKAMOTO
- Laboratory of Immunology and Infection Control, Department
of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Kanagawa,
Japan
| | - Atsushi MIURA
- Laboratory of Immunology and Infection Control, Department
of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Kanagawa,
Japan
| | - Ryota ITO
- Laboratory of Immunology and Infection Control, Department
of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Kanagawa,
Japan
| | - Toshiki KAMADA
- Laboratory of Immunology and Infection Control, Department
of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Kanagawa,
Japan
| | - Yoichi MIZUKAMI
- Institute of Gene Research, Yamaguchi University Science
Research Center, Yamaguchi, Japan
| | - Keiko KAWAMOTO
- Laboratory of Immunology and Infection Control, Department
of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Kanagawa,
Japan
| |
Collapse
|
3
|
Tomono T, Yagi H, Igi R, Tabaru A, Fujimoto K, Enomoto K, Ukawa M, Miyata K, Shigeno K, Sakuma S. Mucosal absorption of antibody drugs enhanced by cell-penetrating peptides anchored to a platform of polysaccharides. Int J Pharm 2023; 647:123499. [PMID: 37832700 DOI: 10.1016/j.ijpharm.2023.123499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 09/15/2023] [Accepted: 10/08/2023] [Indexed: 10/15/2023]
Abstract
Our previous studies demonstrated that L-octaarginine grafted onto hyaluronic acid via a tetraglycine spacer significantly enhanced intranasal absorption of protein drugs with a molecular weight (Mw) of 22 kDa or less. The present study focused on its potential as an absorption enhancer for antibody drugs with a larger Mw and the enhancement mechanism. When ranibizumab (48 kDa) alone was intranasally administered in mice, its absolute bioavailability was 0.67% on average. The mean bioavailability elevated to 6.2% under coadministration with tetraglycine-L-octaarginine-linked hyaluronic acid. A similar result was observed under substitution of ranibizumab with certolizumab pegol (91 kDa), although bioavailability itself decreased with the Mw increase, irrespective of coadministration with the hyaluronic acid derivative. Rat experiments also revealed that coadministration with the polysaccharide derivative resulted in significant enhancement of intranasal absorption of trastuzumab (148 kDa). In vitro studies using gene-knocked down cells indicated that syndecan-4-induced macropinocytosis played a crucial role on acceleration of antibody uptake into epithelial cells on the nasal mucosa, irrespective of their Mw. It appeared that neither clathrin heavy chain nor caveolin-1 involved in cellular uptake of antibodies. Tetraglycine-L-octaarginine-linked hyaluronic acid was concluded to be a promising delivery tool that possessed universal absorption-enhancing abilities independent to Mw of biologics.
Collapse
Affiliation(s)
- Takumi Tomono
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Haruya Yagi
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Ryoji Igi
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Akihiro Tabaru
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Koichi Fujimoto
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Kaho Enomoto
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Masami Ukawa
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan
| | - Kohei Miyata
- Life Science Materials Laboratory, ADEKA Co., 7-2-34, Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Koichi Shigeno
- Life Science Materials Laboratory, ADEKA Co., 7-2-34, Higashiogu, Arakawa-ku, Tokyo 116-8553, Japan
| | - Shinji Sakuma
- Faculty of Pharmaceutical Sciences, Setsunan University, 45-1, Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan.
| |
Collapse
|